



Vaccines and Global Health: The Week in Review
29 March 2025 :: Issue 792
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

:: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

Safeguarding immunisation: a core function of WHO

Correspondence

Rebecca F Grais on behalf of SAGE and RITAG

The Lancet Online first March 24, 2025

[Editor's text bolding]

Vaccination remains the most cost-effective public health intervention, preventing millions of deaths and reducing disease burden worldwide.¹ However, their impact is rendered meaningless if vaccines are not epidemiologically relevant to the populations they serve, are not accepted by communities, or are not effectively delivered through routine or mass immunisation programmes. As history has shown, immunisation programmes have always faced threats—from political instability to misinformation—and these challenges are growing more severe in today's global landscape.²

The integrity of immunisation decision making must be upheld through robust, evidence-based guidance tailored to the needs of individual countries.

The normative function underpinning the global immunisation structure—comprising the Immunization, Vaccines and Biologicals department at WHO, the Strategic Advisory Group of Experts on Immunization (SAGE), the Regional Immunization Technical Advisory Groups (RITAGs), and the National Immunization Technical Advisory Groups—plays a vital role in ensuring that vaccine policies are informed by scientific data and contextual realities.^{3,4}

Together they produce WHO Vaccine Position Papers that serve as global public goods, providing updated and harmonised guidance to support national immunisation programmes.⁵ These structures are essential to help countries to maintain the credibility and effectiveness of vaccination strategies.

Amid rapid transformations in global health governance, it is imperative that these support mechanisms are not only preserved, but reinforced. Countries are facing unprecedented threats today, including emerging infectious disease outbreaks, vaccine-preventable disease resurgence, mass migration, and geopolitical instability.⁶ Amid these challenges, access to sound immunisation policies, underpinned by rigorous technical guidance, is more crucial than ever. The erosion of these structures would significantly undermine the ability of national programmes to respond effectively to public health threats.

Despite the multitude of commentaries, debates, and concerns regarding the future of global health institutions, **we must highlight a function that remains largely underappreciated, yet indispensable—the role of WHO in coordinating and upholding these immunisation guidance mechanisms.** The ongoing reforms must not overshadow or weaken WHO's ability to provide this vital support, which underpins national and regional immunisation decision-making structures.⁷

Moreover, strengthening these frameworks requires increased financial and political commitment from global health stakeholders. The COVID-19 pandemic has shown the fragility of immunisation systems when not adequately resourced, leading to disruptions in routine vaccinations and setbacks in disease control efforts.⁸ Addressing these vulnerabilities necessitates global collaboration and sustained investment in technical advisory bodies and WHO guidance mechanisms.

Although discussions on reform are necessary and should continue, they must not come at the cost of dismantling the frameworks that have enabled global health progress. **We urge global health**

stakeholders to recognise and protect this crucial normative function of WHO, ensuring that technical guidance for immunisation, including policies and strategies, remains a cornerstone of its mandate. Without this guidance, the world risks losing one of the most effective tools for disease prevention, ultimately jeopardising decades of progress vaccines have contributed to global health.[9,10](#)

All signatories are either SAGE members or RITAG chairs. SAGE members: Yemane Berhane, Ghassan Dbaibo, Rebecca F Grais, Sonali Kochhar, Gabriel Leung, Shabir Madhi, Ziad Memish, Kim Mulholland, Hanna Nohynek, Saad Omer, Punnee Pitisuttithum, Anthony Scott, Cristiana Toscano, and Carla Vizzotti. RITAG chairs: Rakesh Aggarwal, J Peter Figueroa, Ezzeddine Mohsni, Chris Morgan, Helen Rees, and Ole Wichmann. I declare no competing interests.

.....
.....

Top F.D.A. Vaccine Official Resigns, Citing Kennedy's 'Misinformation and Lies'

Dr. Peter Marks, a veteran of the agency, wrote that undermining confidence in vaccines is irresponsible and a danger to public health.

The New York Times, Published March 28, 2025 Updated March 29, 2025, 4:39 p.m. ET
By [Christina Jewett](#), [Sheryl Gay Stolberg](#) and [Noah Weiland](#)

The Food and Drug Administration's top vaccine official, Dr. Peter Marks, resigned under pressure Friday and said that Health Secretary Robert F. Kennedy Jr.'s aggressive stance on vaccines was irresponsible and posed a danger to the public.

"It has become clear that truth and transparency are not desired by the secretary, but rather he wishes subservient confirmation of his misinformation and lies," [Dr. Marks wrote](#) to Sara Brenner, the agency's acting commissioner. He reiterated the sentiments in an interview, saying: "This man doesn't care about the truth. He cares about what is making him followers."

Dr. Marks resigned after he was summoned to the Department of Health and Human Services Friday afternoon and told that he could either quit or be fired, according to a person familiar with the matter. Dr. Marks led the agency's Center for Biologics Evaluation and Research, which authorized and monitored the safety of vaccines and a wide array of other treatments, including cell and gene therapies...

Excerpt from resignation letter:

...As you are aware, I was willing to work to address the Secretary's concerns regarding vaccine safety and transparency by hearing from the public and implementing a variety of different public meetings and engagements with the National Academy of Sciences, Engineering, and Medicine. However, it has become clear that truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies.

My hope is that during the coming years, the unprecedented assault on scientific truth that has adversely impacted public health in our nation comes to an end so that the citizens of our country can fully benefit from the breadth of advances in medical science...

.....
.....

BMGF – Mark Suzman’s Statement on Proposed Cuts to Global Vaccines

Statement Mar 26, 2025 BMGF - Gates Foundation

I am deeply disturbed by news reports that the U.S. Administration is considering withdrawing its support for Gavi. If true, and if Congress allows this to happen, the impacts will be devastating, including possibility of hundreds of thousands, if not millions, of preventable deaths, especially among mothers and children. We are going to do everything possible to convince the Administration and the Congress to reverse these actions if true.

.....
.....

Decades of progress in reducing child deaths and stillbirths under threat, warns the United Nations

Number of under-five deaths declined to 4.8 million in 2023, while stillbirths remained around 1.9 million, according to two new UN reports

Joint News Release – UN IGME: UNICEF, World Health Organization, the World Bank Group, Population Division of the United Nations Department of Economic and Social Affairs

25 March 2025 Geneva/New York/Washington D.C.

The number of children dying globally before their fifth birthday declined to 4.8 million in 2023, while stillbirths declined modestly, still remaining around 1.9 million, according to two new reports released today by the United Nations Inter-agency Group for Child Mortality Estimation (UN IGME).

Since 2000, child deaths have dropped by more than half and stillbirths by over a third, fuelled by sustained investments in child survival worldwide. In 2022, the world reached a historic milestone when child deaths dropped slightly below 5 million for the first time. **However, progress has slowed and too many children are still being lost to preventable causes.**

"Millions of children are alive today because of the global commitment to proven interventions, such as vaccines, nutrition, and access to safe water and basic sanitation," said UNICEF Executive Director Catherine Russell. "Bringing preventable child deaths to a record low is a remarkable achievement. But without the right policy choices and adequate investment, we risk reversing these hard-earned gains, with millions more children dying from preventable causes. We cannot allow that to happen."

Decades of progress in child survival are now at risk as major donors have announced or indicated significant funding cuts to aid ahead. Reduced global funding for life-saving child survival programmes is causing health-care worker shortages, clinic closures, vaccination programme disruptions, and a lack of essential supplies, such as malaria treatments.

These cuts are severely impacting regions in humanitarian crises, debt-stricken countries, and areas with already high child mortality rates. Global funding cuts could also undermine monitoring and tracking efforts, making it harder to reach the most vulnerable children, the Inter-agency Group warned.

"From tackling malaria to preventing stillbirths and ensuring evidence-based care for the tiniest babies, we can make a difference for millions of families," said Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization. "In the face of global funding cuts, there is a need more than ever to step up collaboration to protect and improve children's health."...

Almost half of under-five deaths happen within the first month of life, mostly due to premature birth and complications during labour. **Beyond the newborn period, infectious diseases, including acute respiratory infections such as pneumonia, malaria, and diarrhoea, are the leading causes of preventable child death.** Meanwhile, 45% of late stillbirths occur during labour, often due to maternal infections, prolonged or obstructed labour, and lack of timely medical intervention.

Better access to quality maternal, newborn, and child health care at all levels of the health system will save many more lives, according to the reports. This includes promotive and preventive care in communities, timely visits to health facilities and health professionals at birth, high-quality antenatal and postnatal care, **well-child preventive care such as routine vaccinations** and comprehensive nutrition programmes, diagnosis and treatment for common childhood illnesses, and specialized care for small and sick newborns...

The reports also show that where a child is born greatly influences their chances of survival. The risk of death before age five is 80 times higher in the highest-mortality country than the lowest-mortality country, for example, while a child born in sub-Saharan Africa is on average 18 times more likely to die before turning five than one born in Australia and New Zealand. Within countries, the poorest children, those living in rural areas, and those with less-educated mothers face the higher risks.

Stillbirth disparities are just as severe, with nearly 80% occurring in sub-Saharan Africa and Southern Asia, where women are six to eight times more likely to experience a stillbirth than women in Europe or North America. Meanwhile, women in low-income countries are eight times more likely to experience a stillbirth than those in high-income countries.

“Disparities in child mortality across and within nations remain one of the greatest challenges of our time,” said the UN DESA Under-Secretary-General, Li Junhua. “Reducing such differences is not just a moral imperative but also a fundamental step towards sustainable development and global equity. Every child deserves a fair chance at life, and it is our collective responsibility to ensure that no child is left behind.”

UN IGME members call on governments, donors, and partners across the private and public sectors to protect the hard-won gains in saving children’s lives and accelerate efforts. Increased investments, service integration, and innovations are urgently needed to scale up access to proven life-saving health, nutrition, and social protection services for children and pregnant mothers.

[Download multimedia content](#)

[The UN IGME child mortality report](#)

[The UN IGME stillbirth report](#)

About UN IGME

The United Nations Inter-agency Group for Child Mortality Estimation or UN IGME was formed in 2004 to share data on child mortality, improve methods for child mortality estimation, report on progress towards child survival goals and enhance the capacity of countries to produce timely and properly evaluated estimates of child mortality. UN IGME is led by UNICEF and includes the World Health Organization, the World Bank Group and the Population Division of the United Nations Department of Economic and Social Affairs.

.....
.....

Multi-country outbreak of mpox, External situation report #49 - 28 March 2025

KEY FIGURES				
Reporting period: 1 January 2022 – 28 February 2025				
Area	Number of reported confirmed cases		Number of deaths among confirmed cases	Number of reporting countries
Global	132 797		304	131
Reporting period: 1 January 2024 – 16 March 2025				
Area	Number of reported confirmed cases		Number of deaths among confirmed cases	
	2024	2025	2024	2025
Africa	19 737	7063	66	28
Democratic Republic of the Congo ¹	14 806	3207	43	4
Uganda	1339	2802	12	19
Burundi	2946	699	1	0
Reporting period: last six weeks, 3 February – 16 March 2025				
Africa	3170		15	
Democratic Republic of the Congo	1134		0	
Uganda	1504		10	
Burundi	286		0	

1 The national-level case counts for the Democratic Republic of the Congo indicated are based on the national laboratory database for mpox.

2 Comparisons with other countries should be interpreted with caution, given the contextual differences between countries in elements of their respective mpox responses like diagnostic and disease surveillance reporting capacity.

Highlights

:: Updated global surveillance data show that 3191 new confirmed mpox cases were reported globally to WHO for February 2025, an 18.2% decline from the preceding month, and most cases (88%) were detected in the African Region.

:: In the last six weeks, Uganda has reported the highest number of confirmed mpox cases globally, with up to 300 new cases per week.²

:: The Democratic Republic of the Congo continues to be cumulatively the most affected country in the Region since the beginning of the outbreak. The number of suspected cases is plateauing and confirmed cases have decreased in recent weeks, however it is unclear if this reflects a real decline given reductions in testing in recent weeks. Both clade Ia and Ib continue to circulate in the country.

:: Burundi shows a consistent decreasing trend of confirmed cases with less than 50 new cases per week, down from over 200 cases per week at its peak, and an overall very low case fatality ratio with one death among 3645 reported cases.

:: Brazil, the Republic of Congo and the United Republic of Tanzania have reported their first cases of mpox due to clade Ib MPXV.

:: The Republic of Congo is the first country where co-circulation of clade Ia and Ib MPXV has been documented outside of the Democratic Republic of the Congo.

:: Epidemiological data on the number of cases detected in Tanzania and their broad geographic distribution suggests that community transmission is ongoing in the country.

:: The full proceedings of the meeting of the Emergency Committee convened under the provisions of the International Health Regulations 2005 (IHR, 2005) on 25 February 2025 have been published.

WHO has developed an [interactive dashboard](#) that offers a comprehensive overview of deployments by WHO, GOARN, Standby and other partners in support of the mpox response.

[Excerpt]

5. Access to and delivery of countermeasures

Access and Allocation Mechanism (AAM)

Vaccines

:: WHO continues to provide technical support to accelerate implementation and uptake of mpox vaccination in affected countries for people at risk, in support of controlling the surge in mpox cases on the African continent.

:: A total of 1 137 300 doses have been allocated in two rounds to 12 countries (Angola, the Central African Republic, Côte d'Ivoire, the Democratic Republic of the Congo, Guinea, Kenya, Liberia, Nigeria, Rwanda, Sierra Leone, South Africa, and Uganda)

:: To date, 935 480 vaccine doses have been delivered to eight countries, including 50 000 doses of LC16m8 vaccine from Japan to the Democratic Republic of the Congo in January 2025.

:: Vaccination activities have started in five countries (the Central African Republic, Democratic Republic of the Congo, Nigeria, Rwanda, and Uganda), with Sierra Leone and Liberia due to begin this week. On 22 February 2025, the Democratic Republic of the Congo intensified vaccination activities targeting those older than one year of age in the five most affected health zones of Kinshasa. A total of 407 816 persons were vaccinated with one dose of the MVA-BN vaccine and among those vaccinated, 158 493 (39%) were children and adolescents aged one to 17 years of age. Vaccination was planned for 15 (out of 422) health areas in five (out of 35) health zones in Kinshasa.

:: South Sudan, the United Republic of Tanzania, and Zambia are preparing national response plans and are likely to submit vaccine requests to the AAM soon.

:: From 10 – 13 March 2025, WHO convened the Strategic Advisory Group of Experts on immunization (SAGE). During this meeting, **SAGE members re-emphasized strategies of dose sparing (single dose schedule, or fractional dosing with intradermal administration) during times of supply constraints in outbreak response situations.** Highlights of discussions held during the meeting can be found [here](#).

:: Bavarian Nordic's position on product liability: When national regulatory authorities allow age indications which are not on the label of the product (e.g. one year and above, or 12 years and above) in the Marketing Authorization (MA) or Emergency Use Authorization (EUA), Bavarian Nordic covers the product liability as per the indicated authorized age groups.

:: The Democratic Republic of the Congo and Japan are working to re-establish the supply of LC16m8 vaccine to the country following a period of disruption due to insecurity.

:: The AAM partners continue to work together to ensure countries receive guidance to get operational funds for implementation of the national vaccination plans.

.....
.....

Polio – PHEIC

Polio this week – 26 March 2025

Headlines

:: Seroprevalence surveys play a vital role in measuring population immunity, guiding immunization strategies, and assessing program performance in the context of polio eradication efforts. [This article](#) looks at the impact of novel oral polio vaccine type 2 (nOPV2) in Nigeria, with study findings demonstrating the vaccine's strong safety and immunogenicity characteristics.

:: Public health, war and cross-border challenges: the recent cVDPV2 outbreak in Gaza. [This article](#) underscores the need for coordinated response in conflict-affected regions and reflects the significance of global health collaboration in outbreak response management.

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: 24 WPV1-positive environmental samples
- Angola: one cVDPV2 case and one cVDPV2-positive environmental sample
- Chad: two cVDPV2-positive environmental samples
- Djibouti: two cVDPV2-positive environmental samples
- Israel: one cVDPV2-positive environmental sample
- Nigeria: three cVDPV2 cases and three cVDPV2-positive environmental samples

.....
.....

Emergency use of unproven clinical interventions outside clinical trials: ethical considerations

WHO 25 March 2025 | Technical document

Overview

This document is intended to provide policy-makers, authorities in charge of the prevention and management of a public health emergency, such as ministries of health, national regulatory authorities and national disaster management agencies, health-care workers, ethics committees and others, with:
:: an updated version of the ethical framework for use of unproven clinical interventions outside clinical trials during public health emergencies (the MEURI ethical framework),
:: general and operational recommendations for implementing the framework and
:: answers to questions that stakeholders may raise.

Executive summary

Prevention and management of public health emergencies often trigger the ethical duty to conduct rigorous research rapidly. The primary aim of such research should be, on the one hand, to evaluate which unproven interventions – including “off-label” interventions – are safe and effective for treating or preventing a disease or condition associated with the public health emergency and, on the other, to avoid diffusion of unproven interventions that are unsafe or ineffective.

In exceptional circumstances, emergency use of interventions for which there is insufficient evidence of safety or efficacy for regular use in health systems is ethically permissible outside clinical trials or other research contexts, if the primary aim is clinical benefit for individual people or groups or benefit for populations, and if such use during public health emergencies complies with a sound ethical framework that ensures adequate justification, ethical and regulatory oversight, consent process and contribution to evidence.

During the outbreak of Ebola virus disease (EBV) in West Africa in 2014, WHO issued a framework for the ethical permissibility of use of unproven interventions outside clinical trials during public health emergencies. This framework, “monitored emergency use of unregistered and experimental interventions” (MEURI), known as **“the MEURI ethical framework”, avoids the common yet misleading designation of “compassionate use”,** which is associated with too narrow a scope of unproven interventions and is not based on harmonized ethical and regulatory criteria (see glossary, Reasons for avoiding the “compassionate use” designation).

Emergency use of unproven clinical interventions outside clinical trials – including “off-label” interventions – has surged during the COVID-19 pandemic, with unjustified, unconstrained use of unproven interventions, which raises serious ethical concerns.

This document is intended to provide a reminder and an updated version of the ethical framework for emergency use of unproven clinical interventions outside clinical trials, the

MEURI ethical framework, which is a collaborative project of WHO that began in 2014 and a normative product of WHO for its Member States.

2.2 Outline of the MEURI ethical framework

WHO's ethical framework for emergency use of unproven clinical interventions outside clinical trials (the MEURI ethical framework)	
I. Justification	II. Ethical and regulatory oversight
1. Public health emergency	6. Review and approval by authority and ethics committee
2. Absence of proven intervention	7. Minimization of risks
3. Impossibility of initiating research immediately	8. Responsible transition
4. Scientific support based on a favourable risk–benefit analysis	9. Fair access to scarce unproven interventions
5. Effective use of resources	
III. Consent process	IV. Contribution to evidence
10. Individual informed consent	12. Monitoring, collecting and sharing relevant data
11. Community engagement	

2.3 Justification

Summary of ethical criteria

1. Public health emergency	This ethical framework was developed for PHEICs declared by WHO. It may be also useful for Member States in managing non-international public health emergencies, always in compliance with their legal framework.
2. Absence of proven interventions	A national regulatory authority or other relevant authority should determine that there are no proven efficacious or safe clinical interventions or that those available are not satisfactory.
3. Impossibility of initiating research immediately	A national regulatory authority or other relevant authority determines that it is not possible to initiate research on a given intervention for a disease or condition associated with the public health emergency immediately.
4. Scientific support based on favourable risk–benefit analysis	A national regulatory authority or other relevant authority through a qualified scientific advisory committee determines that (4.1.) scientific data are available, at least from laboratory or animal studies, that provide preliminary support for the efficacy and safety of an unproven intervention, and that (4.2) use of unproven clinical interventions outside clinical trials has a favourable risk–benefit analysis.
5. Effective use of resources	A ministry of health or other relevant authority in charge of prevention or management of a public health emergency should ensure that emergency use outside clinical trials does not preclude or delay necessary research on unproven interventions nor divert attention or resources from effective clinical care and/or public health measures that may be crucial.

Commentary

1. Public health emergency	This ethical framework was developed for PHEICs declared by WHO. It may be also useful for Member States in managing non-international public health emergencies, always in compliance with their legal framework.
----------------------------	--



Contents *[click to move among sections]*

:: [Milestones, Perspectives](#)

:: [WHO](#)

[*:: Organization Announcements*](#)
[*:: Journal Watch*](#)
[*:: Pre-Print Servers*](#)

.....
.....

WHO & Regional Offices [to 29 Mar 2025]

<https://www.who.int/news>

Selected News/Announcements/Statements

25 March 2025 *News release*

[**New WHO guidance calls for urgent transformation of mental health policies**](#)

25 March 2025 *Statement*

[**Types of data requested to inform May 2025 COVID-19 vaccine antigen composition deliberations**](#)

25 March 2025 *Joint News Release*

[**Decades of progress in reducing child deaths and stillbirths under threat, warns the United Nations**](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 27 March 2025

[**Strengthening laboratory capacity revolutionizes TB treatment in Congo**](#)

:: 27 March 2025

[**Zimbabwe strengthens polio surveillance with new environmental laboratory**](#)

:: 24 March 2025

[**Togo makes progress in the fight against tuberculosis**](#)

:: 24 March 2025

[**Advancing tuberculosis diagnostics to reach more people in the African region**](#)

WHO Region of the Americas PAHO

:: 27 Mar 2025

[**India-UN Fund Supports 15 Caribbean Countries in Eliminating Mother-to-Child Transmission of Diseases**](#)

Bridgetown, Barbados, 27 March 2025 (PAHO/WHO) - In an ambitious move to combat mother-to-child transmission of diseases like HIV, Syphilis, Hepatitis B, and Chagas disease, 15 Caribbean nations are coming together under a project funded by the India-United Nations Development Partnership Fund and implemented by the Pan American Health...

:: 26 Mar 2025

[**Despite an overall decrease in premature mortality in the Americas, just five countries are on track to achieve the 25% reduction target by 2025**](#)

Brasilia, March 26, 2025 (PAHO) - While premature mortality from non-communicable diseases (NCDs) such as hypertension, diabetes and cancers, has dropped in the Americas over the past decade, from 15.2% in 2010 to 14% in 2021, just five countries of the Region are on track to reach the global target of a 25% reduction in premature mortality from...

:: 25 Mar 2025

[**Countries of the Americas make progress against trachoma**](#)

Washington D.C., March 25, 2025 (PAHO) — Over the past two years, countries of the Americas have made significant progress towards eliminating trachoma, the leading cause of infectious blindness worldwide. These advances are part of the Initiative for the Elimination of Trachoma in the Americas, led by the Pan American Health Organization (PAHO)...

:: 24 Mar 2025

[While TB cases continue to rise in the Americas, new innovations promise improvements in early diagnosis and treatment](#)

Washington D.C. 24 March 2025 (PAHO) – In the Region of the Americas, cases of tuberculosis (TB) have increased 20% over the past decade, and deaths have also shown an upward trend. On World Tuberculosis Day, celebrated each year on 24 March, Pan American Health Organization (PAHO) Director, Dr. Jarbas Barbosa has called on countries of the Region...

WHO South-East Asia Region SEARO

:: 27 March 2025

[Statement: 11th Anniversary: South-East Asia Polio-free certification \(2025\)](#)

:: 24 March 2025

[Statement: World TB Day - "Yes! We Can End TB: Commit, Invest, Deliver"](#)

WHO European Region EURO

:: 26 March 2025 *News release*

[WHO launches first-ever collaborating centre on risk communication, community engagement and infodemic management](#)

:: 24 March 2025 *Media release*

[Childhood tuberculosis cases rise by 10%: a disturbing wake-up call for European Region](#)

WHO Eastern Mediterranean Region EMRO

:: **[WHO and Pakistan call for urgent investment to end tuberculosis](#)** 26 March 2025

:: **[World TB Day 2025](#)** 24 March 2025

:: **[United to end tuberculosis across Afghanistan](#)** 24 March 2025

WHO Western Pacific Region

:: 24 March 2025 *News release*

[WHO in the Western Pacific urges decisive action to end TB](#)

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

[Multi-country outbreak of mpox, External situation report #49 - 28 March 2025](#)

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[28 March 2025 | Cholera - Angola](#)

[27 March 2025 | Measles - United States of America](#)

.....

Weekly Epidemiological Record

Vol. 100, Nos. 13/14, pp. 103–122 28 March 2025

<https://www.who.int/publications/journals/weekly-epidemiological-record>

PDF: <https://iris.who.int/bitstream/handle/10665/380900/WER10013-14-eng-fre.pdf>

:: Genetic and antigenic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness

.....

New WHO Publications

<https://www.who.int/publications>

Selected

28 March 2025

[**Joint external evaluation of the IHR \(2005\) core capacities of Mongolia**](#)

28 March 2025

[**Highlights from the Global Malaria Programme: annual report 2024**](#)

Overview

In April 2024, the Global Malaria Programme unveiled a new operational strategy describing its technical direction for the period 2024–2030. The strategy focuses on four key levers to accelerate malaria responses worldwide: technical leadership, norms and standards, new tools and innovation, and strategic information for impact. This report documents the Programme’s progress in implementing the strategy in its first year.

28 March 2025

[**Quality of conduct and interpretation of insecticide susceptibility in bioassays using new insecticides...**](#)

27 March 2025

[**Report on the global arbovirus surveillance and response capacity survey 2021-2022**](#)

25 March 2025

[**Emergency use of unproven clinical interventions outside clinical trials: ethical considerations**](#)

Overview

This document is intended to provide policy-makers, authorities in charge of the prevention and management of a public health emergency, such as ministries of health, national regulatory authorities and national disaster management agencies, health-care workers, ethics committees and others, with:

- :: an updated version of the ethical framework for use of unproven clinical interventions outside clinical trials during public health emergencies (the MEURI ethical framework),
- :: general and operational recommendations for implementing the framework and
- :: answers to questions that stakeholders may raise.

25 March 2025

[**Ethics and governance of artificial intelligence for health: Guidance on large multi-modal models**](#)

Overview

Artificial Intelligence (AI) refers to the capability of algorithms integrated into systems and tools to learn from data so that they can perform automated tasks without explicit programming of every step by a human. Generative AI is a category of AI techniques in which algorithms are trained on data sets

that can be used to generate new content, such as text, images or video. This guidance addresses one type of generative AI, large multi-modal models (LMMs), which can accept one or more type of data input and generate diverse outputs that are not limited to the type of data fed into the algorithm. It has been predicted that LMMs will have wide use and application in health care, scientific research, public health and drug development. LMMs are also known as “general-purpose foundation models”, although it is not yet proven whether LMMs can accomplish a wide range of tasks and purposes.

25 March 2025

[Report of existing technologies used to screen and detect substandard and falsified medical products](#)

25 March 2025

[Joint national/international Expanded Programme on Immunization and vaccine preventable disease surveillance review and post-introduction evaluation for pneumococcal conjugate, influenza and COVID-19 vaccines](#)

Overview

The joint national/international Expanded Programme on Immunization (EPI) and vaccine-preventable disease surveillance review and post-introduction evaluation of pneumococcal conjugate, influenza and COVID-19 vaccines was conducted in Bhutan on 18–29 March 2024.

It recognized the considerable success achieved in preventing, controlling, and eliminating vaccine-preventable diseases and in new vaccine introduction. The foundation for Bhutan’s success in health lies in its investment in primary health care and a competent and dedicated health workforce.

24 March 2025

[Global network of WHO collaborating centres for bioethics: progress report 2022-2023](#)

24 March 2025

[Interim guidance on social and behavioural research for the mpox public health response, March 2025](#)

Overview

This interim guidance aims to clarify standards for high-quality, ethical, social and behavioural research to strengthen the public health response to the ongoing mpox PHEIC for community protection. The guidance is particularly relevant to rapid research that aims to inform near- to real-time decision-making and action but is equally applicable to longer-term research that may be critical for informing future outbreak preparedness and response.

.....
.....

USA – HHS, FDA, CDC+

Editor’s Note:

We employ bolded red text below to identify observations we assess might be useful to readers.

HHS

[News](#)

[HHS Announces Transformation to Make America Healthy Again](#)

Washington, D.C. — March 27, 2025

...:: Strengthening the Centers for Disease Control and Prevention (CDC): the Administration for Strategic Preparedness and Response (ASPR), responsible for national disaster and public health emergency response, will transfer to the CDC, reinforcing its core mission to protect Americans from health threats...

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

The Advisory Committee calendar does not list any future scheduled meetings of VRBPAC. One other advisory committee meeting has been added to the overall calendar in the last week.

CDC/ACIP [U.S.] [to 29 Mar 2025]

<http://www.cdc.gov/media/index.html>

Latest News

No new digest content identified.

ACIP Meetings [to 29 Mar 2025]

Next ACIP Meetings

:: April 15-16

[Draft ACIP April 15-16, 2025 Meeting Agenda \(posted 3-24-2025\)](#)

[Previous ACIP Feb. 26-28, 2025 Meeting Agenda \(rescheduled, posted 1-17-2025\)](#)

:: June 25-26

:: October 22-23

National Vaccine Program

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

MMWR Weekly

<https://www.cdc.gov/mmwr/index2025.html>

March 27, 2025 / No. 10

[PDF of this issue](#)

No new digest content identified.

.....

.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 24-27 March 2025](#)

Five new medicines recommended for approval; another seven medicines recommended for extension of their therapeutic indications

28 March 2025

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

News

COVID-19 vaccination reduces risk of 'long COVID' in adults

25 Mar 2025

News

Childhood tuberculosis cases rise by 10%: a disturbing wake-up call for Europe

24 Mar 2025

Surveillance and monitoring

Does COVID-19 vaccination reduce the risk and duration of post COVID-19 condition?

25 Mar 2025

This report addresses whether COVID-19 vaccination also reduces the risk and/or duration of a wide range of post-acute COVID-19 symptoms, commonly referred to as 'long COVID'.

.....
.....

Africa CDC [to 29 Mar 2025]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Africa CDC and RECs create Synergies between Regional Procurement Mechanisms and the African Pooled Procurement Mechanism (APPM)

27 March 2025

Statement

Statement of His Excellency Dr. Jean Kaseya, Director General of Africa CDC Regarding the Commemoration of the World TB Day 2025

24 March 2025

.....

China CDC+

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 29 Mar 2025]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 29 Mar 2025]

<http://english.nmpa.gov.cn/>

News

Opinions of the General Office of the State Council on Comprehensively Deepening the Reform of Regulation of Drugs and Medical Devices to Promote the High-Quality Development of the Pharmaceutical Industry

2025-03-25

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-03-28 / No. 13

[PDF of this issue](#)

- Perspectives: Commit, Invest and Deliver: Towards Achieving End Tuberculosis Strategy Goals Through Active Case Finding and Preventive Treatment in China
- Vital Surveillances: Serotype Distribution, Virulence, and Antibiotic Resistance Genomic Characterization of Group B Streptococcus — China, 1998–2024
- Preplanned Studies: Differences Between the Local and Migrant Populations in Healthcare Service Use and Direct Cost of Tuberculosis Treatment — Shanghai Municipality, China, 2020–2021
- Preplanned Studies: Using Phylogenetic Analysis to Detect National and International Dimensions of Hepatitis C Virus 1b Transmission Clusters — China, 1989–2021
- Preplanned Studies: Current Status and Factors of Vaccine Hesitancy in Tetanus Vaccination Among Traumatic Patients — China, 2024

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

Organization Announcements

Paul G. Allen Frontiers Group [to 29 Mar 2025]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 29 Mar 2025]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

Statement Mar 26, 2025

Mark Suzman's Statement on Proposed Cuts to Global Vaccines

I am deeply disturbed by news reports that the U.S. Administration is considering withdrawing its support for Gavi. If true, and if Congress allows this to happen, the impacts will be devastating, including possibility of hundreds of thousands, if not millions, of preventable deaths, especially among mothers and children. We are going to do everything possible to convince the Administration and the Congress to reverse these actions if true.

Bill & Melinda Gates Medical Research Institute [to 29 Mar 2025]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 29 Mar 2025]

<https://carb-x.org/>

News

No new digest content identified.

Chan Zuckerberg Initiative [to 29 Mar 2025]

<https://chanzuckerberg.com/newsroom/>

Newsroom

Mar 26, 2025 · 5 min read

[Chan Zuckerberg Initiative Announces Biohub To Develop Breakthrough Imaging Technologies To Observe Cells in Action](#)

The CZ Biohub San Francisco and CZ Imaging Institute will join together to develop novel imaging technologies that provide entirely new insights into human biology, led by Dr. Scott Fraser.

CEPI – Coalition for Epidemic Preparedness Innovations [to 29 Mar 2025]

<http://cepi.net/>

CEPI News, Blog

News

[New funding for vaccine to protect against deadly MERS coronavirus](#)

CEPI's investment will advance Uvax Bio's MERS vaccine candidate into preclinical trials.

23 Mar 2025

:: \$2.6m investment from CEPI to advance Uvax Bio's MERS vaccine candidate into preclinical trials.

:: Nanoparticle design mimics size and shape of MERS virus to trigger enhanced immune response.

:: As one of the deadliest coronaviruses, MERS is prioritised for vaccine research by CEPI.

:: CEPI has also funded the development of COVID-19 vaccines and is supporting new broadly protective coronavirus vaccines and a coronavirus vaccine library.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 29 Mar 2025]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 29 Mar 2025]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [to 29 Mar 2025]

<https://dndi.org/press/press-releases/>

Press Releases

No new digest content identified.

Duke Global Health Innovation Center [to 29 Mar 2025]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 29 Mar 2025]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

24 March 2025

[World TB Day 2025: Our commitment to combatting tuberculosis](#)

Emory Vaccine Center [to 29 Mar 2025]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 29 Mar 2025]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Fondation Mérieux [to 29 Mar 2025]

<http://www.fondation-merieux.org/>

News, Events

Événement co-organisé par la Fondation Mérieux & l'Université de Genève

[25ème Cours avancé de vaccinologie \(ADVAC\)](#)

5-16 mai 2025 - Centre des Pensières, Veyrier-du-Lac (France)

Gavi [to 29 Mar 2025]

<https://www.gavi.org/>

Press Releases

No new digest content identified.

GE2P2 Global Foundation [to 29 Mar 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – March 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 20 Mar 2025](#)

:: [Genomics :: Governance, Ethics, Policy, Practice – A Monthly Digest – March 2025](#)

GHIT Fund [to 29 Mar 2025]

<https://www.ghitfund.org/newsroom/press>

Press Releases
No new digest content identified.

Global Fund [to 29 Mar 2025]
<https://www.theglobalfund.org/en/news/>
News Releases
No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 29 Mar 2025]
<https://www.glopid-r.org/news/>
News
No new digest content identified.

Hilleman Laboratories [to 29 Mar 2025]
<http://www.hilleman-labs.org/>
News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 29 Mar 2025]
<https://www.hhmi.org/news>
Press Room
No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 29 Mar 2025]
<https://www.humanimmunomeproject.org/>
News
No new digest content identified.

IAVI [to 29 Mar 2025]
<https://www.iavi.org/>
Press Releases, Features
No new digest content identified.

INSERM [to 29 Mar 2025]
<https://www.inserm.fr/en/home/>
Press Releases
No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]
<http://www.icmra.info/drupal/en/news>
Selected Statements, Press Releases, Research
No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 29 Mar 2025]

<https://www.ich.org/>

News/Pubs/Press Releases [Selective]

No new digest content identified.

ICRC [to 29 Mar 2025]

<https://www.icrc.org/en/whats-new>

Latest press releases and statements [Selected]

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 29 Mar 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

No new digest content identified.

IPPS - International Pandemic Preparedness Secretariat [to 29 Mar 2025]

<https://ippsecretariat.org/news/>

News

No new digest content identified.

Institut Pasteur [to 29 Mar 2025]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 29 Mar 2025]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

[19th International Congress of Immunology](#)

Vienna, August 17-22, 2025.

IVAC [to 29 Mar 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 29 Mar 2025]

<http://www.ivi.int/>

IVI News & Announcements

[**A path to future preparedness: Why strengthening clinical trials in West Africa is crucial**](#)

[**Four recipients of 2025 IVI – SK bioscience Park MahnHoon Award announced**](#)

Johns Hopkins Center for Health Security [to 29 Mar 2025]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières_[to 29 Mar 2025]

<http://www.msf.org/>

Latest [Selected Announcements]

Gaza-Israel war

[**Access to water, electricity and fuel blocked in Gaza amidst shattered ceasefire**](#)

Press Release 25 Mar 2025

Gaza-Israel war

[**MSF condemns Israeli strike on Nasser hospital in Gaza, calls for protection of health facilities**](#)

Press Release 24 Mar 2025

War and conflict

[**Mass displacement in northern West Bank takes a dramatic toll on Palestinians**](#)

Press Release 24 Mar 2025

Report 19 Mar 2025

National Academy of Medicine - USA [to 29 Mar 2025]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 29 Mar 2025]

<https://www.nationalacademies.org/newsroom>

News

No new digest content identified.

NIH [to 29 Mar 2025]
[http://www.nih.gov/News Releases](http://www.nih.gov/News_Releases)
No new digest content identified.

PATH [to 29 Mar 2025]
<https://www.path.org/media-center/Newsroom> [Selected]
[PATH's commitment to maternal and newborn health and nutrition at N4G Paris Summit](#)
March 26, 2025

Sabin Vaccine Institute [to 29 Mar 2025]
<https://www.sabin.org/press/>
Latest News & Press Releases
No new digest content identified.

UNAIDS [to 29 Mar 2025]
<http://www.unaids.org/en>
News, Stories, Updates
Feature Story
[Impact of US funding cuts on the global AIDS response — 24 March 2025 update](#)
28 March 2025

Countries are continuing to adapt to the recent cuts to US funding for the global HIV response. The impacts of HIV service disruptions are being more clearly understood as more granular information becomes available. [Updates: Eswatini, Zimbabwe, Nigeria, Ethiopia, Kenya, Malawi]

UNICEF [to 29 Mar 2025]
<https://www.unicef.org/media/press-releases>
Latest press releases, news notes and statements [Selected]
Press release 26 March 2025
[At least 14 million children face disruptions to critical nutrition services in 2025 – UNICEF](#)
NEW YORK/PARIS, 26 March 2025 – At least 14 million children are expected to face disruptions to nutrition support and services because of recent and expected global funding cuts, leaving them at heightened risk of severe malnutrition and death – according to initial analyses issued by UNICEF as world leaders gather...

Press release 26 March 2025
[825,000 children trapped as conflict rages in Sudan's Al Fasher and Zamzam internally displaced camp](#)
PORT SUDAN/NEW YORK – 26 March 2025 – Grave violations against children have surged across Sudan's Darfur states since the start of the year, with 110 violations verified in North Darfur alone and a staggering 83 per cent increase in child casualties in Sudan compared to the first quarter of 2024. In Al Fasher, No...

Press release 24 March 2025
[Decades of progress in reducing child deaths and stillbirths under threat, warns the United Nations](#)

GENEVA/NEW YORK/WASHINGTON D.C., 25 March 2025 – The number of children dying globally before their fifth birthday declined to 4.8 million in 2023, while stillbirths declined modestly, still remaining around 1.9 million, according to two new reports released today by the United Nations Inter-agency Group for Child...

Unitaid [to 29 Mar 2025]

<https://unitaid.org/>

Featured News

No new digest content identified

Vaccine Equity Cooperative [nee Initiative] [to 29 Mar 2025]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative (Sabin) [to 29 Mar 2025]

<https://www.vaccineacceptance.org/>

News

[Announcing the 32nd Albert B. Sabin Gold Medal and 2025 Sabin Rising Star Awardees](#)

Dr. Katherine O'Brien will receive the Albert B. Sabin Gold Medal and the Rising Star award will be given to Dr. Livancliff Mbianke at a ceremony in May.

[Undated]

Vaccine Confidence Project [to 29 Mar 2025]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 29 Mar 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

[Vaccine Update Newsletter March 2025](#)

Wellcome Trust [to 29 Mar 2025]

<https://wellcome.org/news/all>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 29 Mar 2025]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

World Bank [to 29 Mar 2025]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 29 Mar 2025]

<https://www.wfpha.org/>

Blog, Events

No new digest content identified.

World Medical Association [WMA] [to 29 Mar 2025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [OIE] [to 29 Mar 2025]

<https://www.oie.int/>

Press Releases, Statements

Article

[Controlling mammalian tuberculosis: An Ethiopian pilot study](#)

[Undated]

.....

.....

ARM [Alliance for Regenerative Medicine] [to 29 Mar 2025]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 29 Mar 2025]

<https://www.bio.org/press-releases>

Press Releases

[BIO Statement on Resignation of Peter Marks from the FDA](#)

March 29, 2025

John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the FDA:

"Under the extraordinary leadership of Dr. Peter Marks, the FDA shepherded in a new era of scientific breakthroughs -- from new vaccines to curative cell and gene therapies that have strengthened and saved the lives of millions of patients and families.

"The U.S. has long been recognized as the world leader in medical and scientific innovation and regulation, grounded in transparency and scientific rigor. We are deeply concerned that the loss of experienced leadership at the FDA will erode scientific standards and broadly impact the development of new, transformative therapies to fight diseases for the American people.

"It is imperative that we retain and recruit scientific expertise and strong leadership at our health agencies and that the high standards that are the hallmark of these health institutions are upheld and advanced. We are committed to working with the new Commissioner and the Administration to support and enable a strengthened and modernized FDA."

New survey: U.S. biotechs warn tariffs could impede access to cures, stifle innovation

March 26, 2025

WASHINGTON (March 26, 2025) -- Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90...

BIO Releases New Report Underscoring the Massive Economic Power of the American Bioeconomy

March 24, 2025

WASHINGTON D.C. – Today, the Biotechnology Innovation Organization (BIO), in partnership with Kearney, a global management consulting firm, released a first-of-its-kind report that assesses the significant economic impact of the U.S. bioeconomy...

DCVMN – Developing Country Vaccine Manufacturers Network [to 29 Mar 2025]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [to 29 Mar 2025]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [to 29 Mar 2025]

<https://ifpma.org/>

News, Statements [Selected]

No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [to 29 Mar 2025]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

IGBA Statement on trade barriers and their impact on healthcare systems and patients' health (March 2025)

The International Generic and Biosimilar medicines Association (IGBA) remains committed to its vision of working to improve patient access to safe, effective, cost-effective, and quality-assured generic and biosimilar medicines.

PhRMA [to 29 Mar 2025]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - No new digest content identified.

Bavarian Nordic

Latest News - No new digest content identified.

Bharat Biotech

Press Releases - No new digest announcements identified

Mar 20: Bharat Biotech Launches India's Only Vertically Integrated Cell and Gene Therapy, Viral Production Facility at Genome Valley

The company is focused on gene and cell therapies to tackle scientific challenges—such as targeted gene expression, immune system modulation, and long-term cell survival
Hyderabad, India, March 20, 2025

BioCubaFarma – Cuba

Últimas Noticias

Reafirman BioCubaFarma y China lazos de cooperación en biotecnología

Resumen: Visita de delegación china al Complejo Industrial Biotecnológico CIGB-Mariel evidencia los importantes resultados, en una primera etapa, del Centro Conjunto China-Cuba en Biotecnología de Yongzhou, en cuanto a: incubación de proyectos de investigación y desarrollo, generación de nuevos datos científicos y publicaciones en revistas especializadas, registros de patentes conjuntas y formación de capital humano altamente calificado.

Autor: BioCubaFarma

Lun, 24/03/2025 - 13:43

Biological E

News - No new digest announcements identified

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

CinnaGen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News

Mar 24, 2025

Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019

Curevac

News - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media - No new digest announcements identified.

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified

Merck

News releases

March 26, 2025

European Commission (EC) Approves Merck's CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases

March 26, 2025

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

Serum Institute

News & Announcements - No new digest announcements identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases

[SK bioscience and IVI Announce the 2025 Recipients of the 'Park MahnHoon Award' Four Honorees Recognized for Contributions to Polio Vaccine Development and Global Immunization Efforts](#)

-Award established in 2021 to honor the legacy of the late Vice Chairman Park MahnHoon ...
2025.03.25

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases

[Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion](#)

Saint Herblain (France), March 24, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France's Island of La Réunion with its vaccine IXCHIQ®. In agreement and with support from the local public health agency, the Agence Régionale de Santé La Réunion, Valneva will provide 40,000 doses starting early April, with an option to provide more, through distribution agreements with the Island's wholesalers...

Vector State Research Centre of Virology and Biotechnology

Home - [Website not responding [404 error]]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

March 2025 Volume 27, Number 3: E167-236

<https://journalofethics.ama-assn.org/issue/regret-moral-psychology-surgical-professionalism>

Issue Theme: Regret in the Moral Psychology of Surgical Professionalism

Along a physician's training path to becoming a surgeon, there are few, if any, formal or structured opportunities to reflect upon regret experiences. But the influences regret can have in surgeons' practices is worth considering, given that some patients suffer poor outcomes despite surgeons' long-term training, sound decision-making, competent practice, best efforts, and good intentions. This theme issue investigates regret as an expression of a surgeon's moral psychological development and their deep internalization of their capacity to harm. This theme issue also considers how we should regard regret and its kindred moral emotions—loss, grief, remorse, shame, guilt—in surgical life, training, and practice.

[Reviewed earlier]

American Journal of Human Genetics

Mar 06, 2025 Volume 112 Issue 3 p457-724

<https://www.cell.com/ajhg/current>

This month in The Journal

Alyson B. Barnes, Sara B. Cullinan

Publication of the 2023 NASEM report sparked discussions on the use of population descriptors in genetics and genomics research. Experts have offered guidance to researchers in various sub-fields, but little guidance has been provided for clinical laboratory settings. In this issue, Hatchell et al. build on their experience in clinical genomics laboratories to provide insight into the relevance of both conventional and ancestry-based population descriptors for genetic testing and reporting. There are advantages and disadvantages to the use of both types of descriptors.

[Reviewed earlier]

American Journal of Infection Control

March 2025 Volume 53 Issue 3 p285-414

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

March 2025 Volume 68 Issue 3 p429-644

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

March 2025 115(3)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 112 (2025): Issue 3 (Mar 2025)

<https://www.ajtmh.org/view/journals/tpmd/112/2/tpmd.112.issue-3.xml>

Editorial Open access

[Routine Detection of Viruses Through Metagenomics: Where Do We Stand?](#)

Svetoslav Nanev Slavov

DOI: <https://doi.org/10.4269/ajtmh.24-0652>

Annals of Internal Medicine

March 2025 Volume 178, Issue 3

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 340 March 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/340/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 29 Mar 2025)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 29 Mar 2025)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 29 Mar 2025)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 29 Mar 2025)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 29 Mar 2025)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 29 Mar 2025)

[Comparing the maternal and neonatal outcomes in vaccinated and unvaccinated pregnant women against COVID-19: a retrospective cohort study](#)

Following the emergence of COVID-19 disease, and considering the limited number of studies regarding vaccination among pregnant women, as well as the differences between the vaccine administered in Iran and th...

Authors: Zahra Gholami, Maryam Mohseni and Poursan Allahbakhshi Nasab

Citation: *BMC Pregnancy and Childbirth* 2025 25:367

Content type: Research Published on: 28 March 2025

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 29 Mar 2025)

[Population-based seroprevalence survey: post-pandemic COVID-19 vaccination, related factors, and geographic distribution of vaccine acceptability in Chile](#)

Prevention of infectious diseases is based on host protection, especially using vaccines. Several factors have been linked to the acceptance of vaccines in the population. Chile achieved high COVID-19 vaccinat...

Authors: Loreto Nuñez-Franz, Paola Rubilar, Mauricio Apablaza, Luis Canales, Lina J. Cortés, Xaviera Molina, Macarena Said, Kathya Olivares, Juan Correa and Muriel Ramírez-Santana

Citation: *BMC Public Health* 2025 25:1176

Content type: Research Published on: 28 March 2025

[A cross-sectional survey of COVID-19 testing status among vaccine recipients in Gombe State, North-Eastern Nigeria](#)

The COVID-19 testing status and vaccine acceptance are two key components of any COVID-19 control program as they are important in evaluating the prevalence of the disease as well as curbing the spread of the ...

Authors: Nafisah Ayinde Sikiru, Ahmad Ibrahim Al-Mustapha, Muftau Oyewo, Bello Shittu Sani, Adeyi Habibah, Muftiat Mopelola Alikinla and Nusirat Elelu

Citation: *BMC Public Health* 2025 25:1153

Content type: Research Published on: 26 March 2025

[Exploring reported causes of vaccine hesitancy among European adolescents and parents: results of a citizen science project](#)

Progress in pediatric immunization is threatened by vaccine hesitancy. While recent estimates show 14–35% of European parents exhibit some degree of hesitancy, little is known about adolescents. We assessed va...

Authors: Pere Millat-Martínez, Ana Mora, Pol Ezquerro Condeminas, Miquel Castelló, Claudia Alsina, Beatriz Fiestas, Matteo Bason, Montserrat Esquerda, Alexandre Perera-LLuna, Begonya Nafria and Quique Bassat

Citation: BMC Public Health 2025 25:1136

Content type: Research Published on: 25 March 2025

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 29 Mar 2025)

[No new digest content identified]

BMJ Evidence-Based Medicine

April 2025 - Volume 30 - 2

<https://ebm.bmj.com/content/30/2>

[Reviewed earlier]

BMJ Global Health

March 2025 - Volume 10 - 3

<https://gh.bmj.com/content/10/3>

[Reviewed earlier]

Bulletin of the World Health Organization

2025 Mar 1; 103(3)

<https://www.who.int/publications/journals/bulletin/>

[Reviewed earlier]

Cell

Mar 06, 2025 Volume 188 Issue 5 p1175-1456

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 51, Issue 2 March 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 117, Issue 3 Pages: 599-857 March 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

March 2025 Volume 47 Issue 3 p179-248
<http://www.clinicaltherapeutics.com/current>
[Reviewed earlier]

Clinical Trials

Volume 22 Issue 1, February 2025
<https://journals.sagepub.com/toc/ctja/22/1>
[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>
[Accessed 29 Mar 2025]
[No new digest content identified]

Contemporary Clinical Trials

Volume 150 March 2025
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/150/suppl/C>
[Reviewed earlier]

The CRISPR Journal

Volume 8, Issue 1 / February 2025
<https://www.liebertpub.com/toc/crispr/8/1>
[Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025
<https://link.springer.com/journal/40142/volumes-and-issues/13-1>
[Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 1 2025
<https://www.tandfonline.com/toc/icmo20/current>
[Reviewed earlier]

Current Opinion in Infectious Diseases

April 2025 - Volume 38 - Issue 2
<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>
Article

[Health inequalities in respiratory tract infections – beyond COVID-19](#)

Ulanova, Marina

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 29 Mar 2025]
[No new digest content identified]

Developing World Bioethics

Volume 25, Issue 1 Pages: 1-79 March 2025
<https://onlinelibrary.wiley.com/toc/14718847/current>
[Reviewed earlier]

Development in Practice

Volume 34, Issue 6, 2024
<https://www.tandfonline.com/toc/cdip20/34/6>
[Reviewed earlier]

Development Policy Review

Volume 43, Issue 2 March 2025
<https://onlinelibrary.wiley.com/toc/14677679/current>
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025
<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>
[New issue; No digest content identified]

Disasters

Volume 49, Issue 1 January 2025
<https://onlinelibrary.wiley.com/toc/14677717/2025/49/1>
[Reviewed earlier]

EMBO Reports

Volume 26 Issue 5 10 March 2025
<https://www.embopress.org/toc/14693178/current>
[Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 2—February 2025
<http://wwwnc.cdc.gov/eid/>
[Reviewed earlier]

Epidemics

Volume 50 March 2025
<https://www.sciencedirect.com/journal/epidemics/vol/50/suppl/C>
[Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 47, Issue 1 Pages: 1-45 January–February 2025

<https://onlinelibrary.wiley.com/toc/25782363/current>

Moral distress in clinical research • Research with incarcerated and homeless women

[Reviewed earlier]

Ethics & International Affairs

Volume 38 - Issue 3 - Fall 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

The European Journal of Public Health

Volume 35, Issue 1, February 2025

<https://academic.oup.com/eurpub/issue/35/1>

[Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

January/February 2025

<https://www.foreignaffairs.com/issues/2025/104/1>

Special Section

Will Trump Change the World?

Forum for Development Studies

Volume 52, 2025 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

Co-creating knowledge in development studies

[Introduction to Special Issue: Co-creating Knowledge in Development Studies](#)

Randi Solhjell & Sören Jeppesen

Pages: 1-5

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 29 Mar 2025]

[No new digest content identified]

Gene Therapy – Nature

Volume 32 Issue 2, March 2025

<https://www.nature.com/gt/volumes/32/issues/2>

[New issue; No digest content identified]

Genetics in Medicines

Volume 27, Issue 3 March 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/3>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 29 Mar 2025]

[No new digest content identified]

Global Health Action

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 29 Mar 2025]

[No new digest content identified]

Global Public Health

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 29 Mar 2025]

[No new digest content identified]

Health and Human Rights

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>

Special Section: Distress Migration and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 4 - October 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 40, Issue 2, March 2025

<https://academic.oup.com/heapol/issue/40/2>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 29 Mar 2025]

[No new digest content identified]

Human Gene Therapy

Volume 36, Issue 5-6 / March 2025

<https://www.liebertpub.com/toc/hum/36/5-6>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

Selected Content

[Reviewed earlier]

Immunity

Mar 11, 2025 Volume 58 Issue 3 p515-766

<https://www.cell.com/immunity/current>
[New issue; No digest content identified]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>
[Accessed 29 Mar 2025]
[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>
[Accessed 29 Mar 2025]
[No new digest content identified]

International Health

Volume 17, Issue 2, March 2025
<https://academic.oup.com/inthealth/issue/17/2>
[Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 2 (Dec 2024)
<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>
[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 2 (2025): February 2025
<https://www.ijcmph.com/index.php/ijcmph/issue/view/121>
[Reviewed earlier]

International Journal of Epidemiology

Volume 54, Issue 1, February 2025
<https://academic.oup.com/ije/issue/54/1>
[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18 Issue 1 2025
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/18/iss/1>
Table of contents
[Reviewed earlier]

JAMA

March 25, 2025, Vol 333, No. 12, Pages 1017-1098
<https://jamanetwork.com/journals/jama/currentissue>
Viewpoint

[**Setting Public Health Priorities in the United States**](#)

Harvey V. Fineberg, MD, PhD

JAMA. 2025;333(12):1025-1027. doi:10.1001/jama.2025.0485

This Viewpoint discusses the challenges facing US leadership in improving the state of the country's public health and outlines 5 classes of candidates for public health intervention and 4 criteria to guide public health priority setting.

A World Without WHO—A Crossroads for US Global Health Leadership

Lawrence O. Gostin, JD; Benjamin Mason Meier, JD, LLM, PhD; Loyce Pace, MPH

JAMA. 2025;333(12):1028-1029. doi:10.1001/jama.2024.28827

The US was instrumental in establishing the World Health Organization (WHO) and has been its largest state funder and most influential member for more than 75 years. Yet there are well-grounded fears that the incoming Trump administration will withdraw the US from WHO membership. Breaking from long-standing leadership in global health, this withdrawal would severely weaken US influence and diplomacy. Instead of withdrawing, the Trump administration should work to reform WHO to face rising health challenges, including H5N1 influenza and mpox clade Ib.

JAMA Health Forum

March 2025, Vol 6, No. 3

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

March 2025, Vol 179, No. 3, Pages 228-356

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBIR Evidence Synthesis

March 2025 - Volume 23 - Issue 3

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

March 2025 Volume 76 Issue 3 p341-526

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 82 (2025)

<https://www.jair.org/index.php/jair>

Contents

[New issue; No digest content identified]

Journal of Community Health

Volume 50, Issue 1 February 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-1>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

Journal of Development Economics

Volume 173 March 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/173/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

March 2025 - Volume 79 - 3

<https://jech.bmj.com/content/79/3>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 18, Issue 1 March 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 3 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

Special Issue: 20th Anniversary Forum

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 1, February 2025

<https://muse.jhu.edu/issue/54278>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 27, Issue 1 February 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-1>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 23, Issue 1 (2025)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 37, Issue 2 Pages: 1-619 March 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

March 2025 - Volume 51 - 3

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 277 February 2025

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/277/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 18, 2025 Issue 1

<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>

[Reviewed earlier]

Journal of Public Health Management & Practice

March/April 2025 - Volume 31 - Issue 2

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 46, Issue 1 March 2025

<https://link.springer.com/journal/41271/volumes-and-issues/46-1>

[Reviewed earlier]

Journal of the Royal Society – Interface

March 2025 Volume 22 Issue 224
<https://royalsocietypublishing.org/toc/rsif/current>
[Reviewed earlier]

Journal of Travel Medicine

Volume 32, Issue 2, March 2025
<https://academic.oup.com/jtm/issue>
[Reviewed earlier]

Journal of Virology

Volume 99 • Number 2 • February 2025
<http://jvi.asm.org/content/current>
[Reviewed earlier]

The Lancet

Mar 29, 2025 Volume 405 Number 10484 p1027-1118
<https://www.thelancet.com/journals/lancet/issue/current>

Articles

[Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial](#)

Fatoumata Diallo, et al. on behalf of the NmCV-5 EPI study team

Interpretation

When compared with a licensed, quadrivalent meningococcal conjugate vaccine, and given alongside other routine vaccines, a single dose of NmCV-5 was safe and elicited a non-inferior immune response in infants aged 9 months and young children aged 15 months.

The Lancet Child & Adolescent Health

Mar 2025 Volume 9 Number 3 p151-210, e4-e9
<https://www.thelancet.com/journals/lanchi/issue/current>
[Reviewed earlier]

Lancet Digital Health

Mar 2025 Volume 7 Number 3 e167-e231
<https://www.thelancet.com/journals/landig/issue/current>
[Reviewed earlier]

Lancet Global Health

Mar 2025 Volume 13 Number 3 e372-e598
<https://www.thelancet.com/journals/langlo/issue/current>
[Reviewed earlier]

Lancet Infectious Diseases

Mar 2025 Volume 25 Number 3 p243-356, e114-e190

<https://www.thelancet.com/journals/laninf/issue/current>
[Reviewed earlier]

Lancet Public Health

Mar 2025 Volume 10 Number 3 e165-e263
<https://www.thelancet.com/journals/lanpub/issue/current>
[Reviewed earlier]

Lancet Respiratory Medicine

Mar 2025 Volume 13 Number 3 p189-288, e17-e19
<https://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 29, Issue 3 March 2025
<https://link.springer.com/journal/10995/volumes-and-issues/29-2>
[New issue; No digest content identified]

Medical Decision Making (MDM)

Volume 45 Issue 3, April 2025
<http://mdm.sagepub.com/content/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 103, Issue 1 Pages: 1-241 March 2025
<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Molecular Therapy

Mar 05, 2025 Volume 33 Issue 3 p825-1304
<https://www.cell.com/molecular-therapy/current>
[Reviewed earlier]

Nature

Volume 639 Issue 8056, 27 March 2025
<https://www.nature.com/nature/volumes/638/issues/8056>
[New issue; No digest content identified]

Nature Biotechnology

Volume 43 Issue 3, March 2025
<https://www.nature.com/nbt/volumes/43/issues/3>
[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 29 Mar 2025)

[Reviewed earlier]

Nature Genetics

Volume 57 Issue 3, March 2025

<https://www.nature.com/ng/volumes/57/issues/3>

[Reviewed earlier]

Nature Human Behaviour

Volume 9 Issue 2, February 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/2>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 24 Issue 3, March 2025

<https://www.nature.com/nrd/volumes/24/issues/3>

[Reviewed earlier]

Nature Reviews Genetics

Volume 26 Issue 3, March 2025

<https://www.nature.com/nrg/volumes/26/issues/3>

[Reviewed earlier]

Nature Reviews Immunology

Volume 25 Issue 3, March 2025

<https://www.nature.com/nri/volumes/25/issues/3>

[Reviewed earlier]

New England Journal of Medicine

Volume 392 No. 12 March 27, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

NEJM Evidence

Volume 4 No. 2 February 2025

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 29 Mar 2025]

Article 29 Mar 2025

[Modeling the impact of early vaccination in an influenza pandemic in the United States](#)

Van Hung Nguyen, Pascal Crépey, Jane M. True

Pediatrics

Volume 155, Issue 3 March 2025

<https://publications.aap.org/pediatrics/issue/155/3>

[Reviewed earlier]

PharmacoEconomics

Volume 43, Issue 3 March 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-3>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 29 Mar 2025)

[On improving the sustainability of peer review](#)

Daniel Routledge, Nonia Pariente, on behalf of the PLOS Biology staff editors

Editorial | published 25 Mar 2025 PLOS Biology

<https://doi.org/10.1371/journal.pbio.3003127>

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 29 Mar 2025)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 29 Mar 2025)

[Childhood vaccination trends among the Maasai nomadic pastoralists: Insights from a community-based vaccine registry in Kenya](#)

Julius Nyerere Odhiambo, Carrie B. Dolan, Evelyn Thompson, Katie O'Neill, John Sankok, Rose Kimani

Research Article | published 25 Mar 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004077>

[Cholera vaccines for the rich, cholera for the poor: While the global cholera vaccine stockpile runs dry, a booming market for high-income countries exemplifies the chasm between commercial interests and global health needs](#)

Adam R. Houston, Stan Houston

Opinion | published 24 Mar 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004359>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 29 Mar 2025)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 29 Mar 2025)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 29 Mar 2025]

[No new digest content identified]

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 29 Mar 2025]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

April 1, 2025 | vol. 122 | no. 13

<https://www.pnas.org/toc/pnas/122/13>

[New issue; No digest content identified]

PNAS Nexus

Volume 4, Issue 2, February 2025

<https://academic.oup.com/pnasnexus/issue/4/2>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 40 - Issue 1 - February 2025

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[New issue; No digest content identified]

Preventive Medicine

Volume 192 March 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/192/suppl/C>

[New issue; No digest content identified]

Proceedings of the Royal Society B

March 2025 Volume 292 Issue 2042

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 240 Pages 1-222 (March 2025)

<https://www.sciencedirect.com/journal/public-health/vol/240/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 18, Issue 1, April 2025

<http://phe.oxfordjournals.org/content/current>

[New issue; No digest content identified]

Public Health Genomics

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

Public Health Reports

Volume 140 Issue 1, January/February 2025

<https://journals.sagepub.com/toc/phrg/140/1>

[Reviewed earlier]

Qualitative Health Research

Volume 35 Issue 3, March 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 21 Issue 1, January 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 29 Mar 2025]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

[No new digest content identified]

Risk Analysis

Volume 45, Issue 2 pages: 265-472 February 2025
<https://onlinelibrary.wiley.com/toc/15396924/current>
[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>
[Accessed 29 Mar 2025]
[No new digest content identified]

Royal Society Open Science

March 2025 Volume 12 Issue 3
<https://royalsocietypublishing.org/toc/rsos/current>
[Reviewed earlier]

Science

Volume 387| Issue 6741| 28 Mar 2025
<https://www.science.org/toc/science/current>

In Depth

[U.S. cuts hamper disease surveillance worldwide](#)

BY Jon Cohen

27 Mar 2025: 1336-1337

Many efforts to prevent outbreaks and track diseases are suddenly in limbo

Policy Forum

[Guiding science in China](#)

BY Andrew Kennedy

27 Mar 2025: 1356-1358

Abstract

China's emergence as a science power is extraordinary. China now publishes more scientific papers than any other country, and the impact of this research (although trickier to measure) is impressive (1). Despite China's remarkable progress, its policymakers continue to grapple with a basic question that all countries face: how to balance between promoting research focused on national priorities and that driven by academic curiosity. This article begins by explaining how Chinese policy-makers have recently stepped up efforts to guide science in keeping with national priorities, including economic, environmental, and national security concerns. It then notes an important countercurrent, particularly the growing interest in "original innovation" and the appreciation that curiosity-driven research has a role to play in this regard. It concludes by noting that China is part of a broader international shift to leverage science for national purposes, and by highlighting the risks this trend entails.

Science and Engineering Ethics

Volume 31, Issue 2 April 2025
<https://link.springer.com/journal/11948/volumes-and-issues/31-2>
[New issue; No digest content identified]

Science Translational Medicine

Volume 17| Issue 791| 26 Mar 2025
<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 29 Mar 2025]

[No new digest content identified]

Social Science & Medicine

Volume 370 April 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/370/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 29 Mar 2025]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 46, Issue 1 February 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-1>

Special Issue on Bioethics and Language

Issue Editor: Matthew Vest

[New issue; No digest content identified]

Travel Medicine and Infectious Diseases

Volume 64 March–April 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/64/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 30, Issue 3 Pages: i-iv, 143-230 March 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 51 2 April 2025

<https://www.sciencedirect.com/journal/vaccine/vol/51/suppl/C>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 29 Mar 2025]

Open Access Article

Assessing Immunization Coverage and the Negative Impact of Local Vaccine Production Cessation in Ecuador

by Esteban Ortiz-Prado, Lisette Carolina Villacreses-Brito, Jorge Vasconez-Gonzalez, Cristina Anabel Jacome, Marlon Arias-Intriago and Juan S. Izquierdo-Condo

Vaccines 2025, 13(4), 348; <https://doi.org/10.3390/vaccines13040348> - 25 Mar 2025

Abstract

Background: The COVID-19 pandemic highlighted vaccine importance while exposing inequities in global immunization, especially in LMICs like Ecuador. Local vaccine production ensures supply, reduces reliance on imports, and boosts health security. Understanding the relationship between local production and vaccination outcomes is crucial to

Open Access Systematic Review

Comparative Analysis of Health Economic Evaluations for Different Influenza Vaccines and Vaccination Strategies in China: A Systematic Review

by Fanxu Kong, Li Cai, Jiayi Zhang, Huijie Zhu, Zhibin Peng, Jiandong Zheng, Yaming Zheng and Hai Fang

Vaccines 2025, 13(3), 332; <https://doi.org/10.3390/vaccines13030332> - 20 Mar 2025

Abstract

Objective: This study systematically reviews health economic evaluations of influenza vaccines in China and synthesizes the evidence on different vaccine categories. Methods: We searched databases, including the China Hospital Knowledge Database, Wanfang, PubMed, Web of Science, and Embase, for studies on the health

Value in Health

March 2025 Volume 28 Issue 3p323-488

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 187 March 2025

<https://www.sciencedirect.com/journal/world-development/vol/187/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 29 Mar 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

[No new digest content identified]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 29 Mar 2025]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 29 Mar 2025]

[Filter: All articles]

[Towards triple elimination of HIV, syphilis and HBV mother-to-child transmission: protocol of a simplified and integrated strategy in Burkina Faso and The Gambia: the TRI-MOM project, phase 1](#)

Erwan Vo Quang, Alice N Guingané, Lauren Périères, Gibril Ndow, Victor Some, Sheriff Badjie, Asta Jobe, Clarisse Gouem, Yusuke Shimakawa, Dramane Kania, Maud Lemoine, Sylvie Boyer, TRI-MOM study group

medRxiv 2025.03.27.25324811; doi: <https://doi.org/10.1101/2025.03.27.25324811>

[Leveraging Global Genetics Resources to Enhance Polygenic Prediction Across Ancestrally Diverse Populations](#)

Oliver Pain

medRxiv 2025.03.27.25324773; doi: <https://doi.org/10.1101/2025.03.27.25324773>

[Prompt Engineering in Large Language Models for Patient Education: A Systematic Review](#)

Aya Mudrik, Girish Nadkarni, Orly Efros, Shelly Soffer, Eyal Klang

medRxiv 2025.03.28.25324834; doi: <https://doi.org/10.1101/2025.03.28.25324834>

[Impact assessment of vaccine-related negative news and incentive measures on vaccine hesitancy in Hong Kong](#)

YIFAN CHEN, Yang Ye, Hsiang-Yu Yuan, Qingpeng Zhang

medRxiv 2025.02.21.25322646; doi: <https://doi.org/10.1101/2025.02.21.25322646> Revision

[Mining Social Media Data for Influenza Vaccine Effectiveness Using a Large Language Model and Chain-of-Thought Prompting](#)

Dongfang Xu, Guillermo López García, Karen O'Connor, Haily Holston, Ari Z Klein, Ivan Flores Amaro, Matthew Scotch, Graciela Gonzalez-Hernandez

medRxiv 2025.03.26.25324701; doi: <https://doi.org/10.1101/2025.03.26.25324701>

[Impact of the COVID-19 Pandemic on Vaccination Coverage in Ecuador: A Pre- and Post-Pandemic Comparative Analysis](#)

José Daniel Sánchez, Kimberlly Pamela Montenegro Cuello, Alejandro Arjuna Rodriguez Proaño

medRxiv 2025.03.26.25324742; doi: <https://doi.org/10.1101/2025.03.26.25324742>

[Assessing MMR Vaccination Strategies in Texas: A Scenario-Based Modeling Study of Measles Outbreaks](#)

Kaiming Bi, Thuy Nguyen, Boya Peng, Trudy Krause, Cecilia Ganduglia Cazaban, Janelle Rios, Cici Bauer, Catherine Troisi, Eric Boerwinkle, Aanand D. Naik
medRxiv 2025.03.25.25324613; doi: <https://doi.org/10.1101/2025.03.25.25324613>

Decolonising Global Health: a scoping review

Daniel E Stewart, Tiruneh Amsalu, Ellie Fairfoot, David Keen, Jessica Keenan, Frances Butcher, Kevin Miles, Ahmed Razavi
medRxiv 2025.03.26.25324588; doi: <https://doi.org/10.1101/2025.03.26.25324588>

Antimicrobial stewardship programs and antibiotic use in Africa: a Systemic review and meta-analysis protocol

Ammas Siraj, Dawit Abrham
medRxiv 2025.03.24.25324562; doi: <https://doi.org/10.1101/2025.03.24.25324562>

Contextualizing future maternal RSV vaccination acceptance and trust among pregnant and lactating women in Kenya: A latent class analysis

Molly A. Sauer, Berhaun Fesshaye, Emily Miller, Jessica Schue, Prachi Singh, Rose Jalang'o, Joyce Nyiro, Christine Karanja-Chege, Rosemary Njogu, Fred Were, Ruth Karron, Rupali J. Limaye
medRxiv 2025.03.24.25324585; doi: <https://doi.org/10.1101/2025.03.24.25324585>

Trust in healthcare providers, information sources, and concerns for new maternal vaccines among pregnant and lactating women in Kenya

Jessica L. Schue, Berhaun Fesshaye, Emily Miller, Prachi Singh, Molly Sauer, Rosemary Njogu, Rose Jalang'o, Joyce Nyiro, Ruth A. Karron, Rupali J. Limaye
medRxiv 2025.03.24.25324583; doi: <https://doi.org/10.1101/2025.03.24.25324583>

Data-driven consideration of genetic disorders for global genomic newborn screening programs

Thomas Minten, Sarah Bick, Sophia Adelson, Nils Gehlenborg, Laura M. Amendola, François Boemer, Alison J. Coffey, Nicolas Encina, Alessandra Ferlini, Janbernd Kirschner, Bianca E. Russell, Laurent Servais, Kristen L. Sund, Ryan J. Taft, Petros Tsipouras, Hana Zouk, ICoNS Gene List Contributors, David Bick, the International Consortium on Newborn Sequencing (ICoNS), Robert C. Green, Nina B. Gold
medRxiv 2024.03.24.24304797; doi: <https://doi.org/10.1101/2024.03.24.24304797> Revision

Population impact of new TB vaccines may depend on efficacy against infectious asymptomatic TB: a modelling study

Hira Tanvir, Rebecca A Clark, Tom Sumner, Katherine C Horton, Tomos O Prÿs-Jones, Roel Bakker, Kirankumar Rade, Vidya Mave, Mark Hatherill, Gavin Churchyard, Rein MGJ Houben, Richard G White
medRxiv 2025.03.24.25323816; doi: <https://doi.org/10.1101/2025.03.24.25323816>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[Website not responding at inquiry]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 29 Mar 2025]

[No new digest content identified]

* * * *

Think Tanks

Brookings [to 29 Mar 2025]

<http://www.brookings.edu/>

Reports, Events

Pharmaceutical & Drug Policy

Will pharmaceutical tariffs achieve their goals?

Marta Wosińska

March 27, 2025

:: Tariffs will provide a strong incentive for increasing U.S. manufacturing of brand-name drugs but not of older, off-patent generic drugs, which represent over 90% of the volume but only a small share of spending.

:: Tariff pressure for both domestic and foreign manufacturers of generics will test their already low margins, potentially leading to product discontinuations or cost cutting that erodes quality. Any production disruptions in the already fragile generic injectable markets are likely to result in shortages.

:: To onshore generic drug production, the administration will need to deploy tools other than tariffs.

Center for Global Development [to 29 Mar 2025]

<https://www.cgdev.org/>

All Research

BRIEFS

A New Era for Global Health: Can African Countries Agree a New Compact with External Donors?

Anastassia Demeshko et al.

March 27, 2025

African health systems are at a crossroads, grappling with systemic challenges including workforce shortages, underfunded infrastructure, and climate-driven health burdens. Volatile financing—driven by unpredictable donor commitments and competing global priorities—has left countries vulnerable to d...

Chatham House [to 29 Mar 2025]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 29 Mar 2025]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 29 Mar 2025]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 29 Mar 2025]
https://www.kff.org/search/?post_type=press-release
Newsroom
No new digest content identified.

McKinsey Global Institute [to 29 Mar 2025]
<https://www.mckinsey.com/mgi/overview>
Latest Research
No new digest content identified.

ODI [Overseas Development Institute] [to 29 Mar 2025]
<https://odi.org/en/publications/>
Publications [Selected]
No new digest content identified.

Pew Research Center [to 29 Mar 2025]
<https://www.pewresearch.org/>
Latest Publications [Selected]
No new digest content identified.

Rand [to 29 Mar 2025]
<https://www.rand.org/pubs.html>
Published Research [Selected]
No new digest content identified.

Urban Institute [to 29 Mar 2025]
<https://www.urban.org/publications>
[**New Research Publications - Selected**](#)

World Economic Forum [to 29 Mar 2025]
<https://agenda.weforum.org/press/>
Media [Selected]
No new digest content identified.

* * * *

Contents [click to move among sections]
:: [Milestones, Perspectives](#)
:: [WHO](#)
:: [Organization Announcements](#)
:: [Journal Watch](#)
:: [Pre-Print Servers](#)

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *